Natera (NASDAQ:NTRA – Get Rating) had its price target reduced by equities research analysts at Piper Sandler from $75.00 to $60.00 in a research note issued to investors on Sunday, The Fly reports. Piper Sandler’s target price would suggest a potential upside of 75.44% from the stock’s previous close. A number of other research analysts […]
Assenagon Asset Management S.A. boosted its position in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) by 37.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 453,179 shares of the medical research company’s stock after acquiring an additional 124,497 shares during the quarter. Assenagon […]
Brown Advisory Inc. grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) by 395.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 343,543 shares of the medical research company’s stock after purchasing an additional 274,205 shares during the period. Brown Advisory Inc. […]
Natera, Inc. (NASDAQ:NTRA – Get Rating) – Research analysts at Piper Sandler reduced their Q1 2022 EPS estimates for Natera in a research note issued to investors on Monday, March 21st. Piper Sandler analyst D. Westenberg now forecasts that the medical research company will earn ($1.39) per share for the quarter, down from their previous […]
Natera (NASDAQ:NTRA – Get Rating) had its price target cut by Piper Sandler from $80.00 to $70.00 in a research note published on Monday morning, MarketBeat reports. They currently have an overweight rating on the medical research company’s stock. Piper Sandler also issued estimates for Natera’s Q1 2022 earnings at ($1.39) EPS, Q2 2022 earnings […]